Virtual Screening of Some Antivirals That Can Be Repurposed As Potential Effective Drugs against SARS-CoV-2
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
SARS-CoV-2 has triggered a big epidemic among people around the world and it is the newest
in the sequence to be prevalent among other infectious diseases. Drug repurposing concept has
been utilized effectively for numerous viral infections. Considering the situation and the urgency,
the idea of drug repurposing for coronavirus infection (COVID-19) is also being studied.
Screening with molecular docking method for 29 antiviral drugs was performed against SARSCoV-2 primary protease proteins (MPP), spike ecto-domain, spike receptor binding domain,
Nsp9 RNA binding protein,and HR2 domain. Among these drugs, Indinavir, Sorivudine,
Cidofovir and Darunavir show minimum docking scores with all key proteins in terms of least
binding energy. For ADME (Absorption, Distribution, Metabolism, and Excretion) analysis, the
top 4 drug candidates were further used to examine their drug profiles for suitability against
SARS-CoV-2. The toxicity testing of top drug candidates showed no significant carcinogenic,
mutagenic or skin irritating impacts. Indinavir may possess some complexity to heart. In
addition, the drug similarity prediction revealed several approved structural analogues such as
Telbivudine, Tenofovir, Amprenavir, Fosamprenavir etc which also could be used to treat viral
infections. The study may speed up the findings of therapeutics against SARS-CoV-2.